Electra Therapeutics (NASDAQ:ETRA) Director Carl Gordon Acquires 49,416 Shares of Stock

Electra Therapeutics, Inc. (NASDAQ:ETRA) Director Carl Gordon bought 49,416 shares of the business’s stock in a transaction that occurred on Friday, November 6th. The shares were bought at an average cost of $7.85 per share, for a total transaction of $387,915.60. Following the completion of the purchase, the director owned 5,230,578 shares of the company’s stock, valued at $41,060,037.30. This represents a 0.95% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Electra Therapeutics Price Performance

NASDAQ:ETRA opened at $7.99 on Wednesday. Electra Therapeutics, Inc. has a 12 month low of $6.86 and a 12 month high of $15.50.

Analyst Ratings Changes

ETRA has been the subject of several research reports. TD Cowen began coverage on Electra Therapeutics in a research note on Tuesday, October 13th. They issued a “buy” rating for the company. HC Wainwright began coverage on Electra Therapeutics in a research report on Monday, October 26th. They issued a “buy” rating and a $30.00 target price for the company. JPMorgan Chase & Co. assumed coverage on Electra Therapeutics in a research note on Thursday, October 22nd. They set an “overweight” rating and a $36.00 price target on the stock. Zacks Research upgraded Electra Therapeutics to a “hold” rating in a report on Wednesday, October 14th. Finally, Evercore started coverage on Electra Therapeutics in a research note on Tuesday, October 13th. They issued an “outperform” rating and a $36.00 price objective for the company. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat, Electra Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $33.50.

Key Headlines Impacting Electra Therapeutics

Here are the key news stories impacting Electra Therapeutics this week:

• Positive Sentiment: Director Carl Gordon, through OrbiMed Advisors, reported purchases totaling 92,116 shares across November 6, 9 and 10, at prices ranging from $7.85 to $8.45 per share. Repeated buying by a director may signal confidence in the company, although it does not guarantee future performance. SEC ownership filing
• Neutral Sentiment: A report said short interest stood at zero shares as of November 10, with zero days to cover. That figure does not indicate meaningful reported short positioning, but it conflicts with the report’s description of a “significant increase,” making the short-interest update difficult to interpret.

Electra Therapeutics Company Profile

Electra Therapeutics, Inc. (NASDAQ: ETRA) is a clinical-stage biotechnology company focused on developing antibody-based medicines for diseases driven by abnormal immune-cell activity. The company’s approach is designed to selectively eliminate or modulate disease-causing immune cells while preserving healthy immune function. Electra’s lead investigational product is ELA026, an antibody targeting SIRPα, a protein involved in immune-cell signaling. The company is evaluating ELA026 in immune-mediated diseases, including systemic sclerosis and other conditions in which macrophages and related immune cells may contribute to disease progression.